Program Detail

Modality
Program #
Program
indication
Presentation

Source
COVID-19 vaccine

Last program update Sep 09, 2021

Source
COVID + Flu vaccine

Last program update Sep 09, 2021

Source
Respiratory Syncytial virus (RSV) vaccine

Last program update Sep 09, 2021

Source
Influenza vaccine

Last program update Sep 09, 2021

Source
Pediatric RSV + hMPV vaccine

Last program update Sep 09, 2021

Source
Human metapneumovirus and parainfluenza virus 3 (hMPV/PIV3) vaccine

Last program update Sep 09, 2021

Source
Cytomegalovirus (CMV) vaccine

Last program update Sep 09, 2021

Source
Zika vaccine

Last program update Aug 05, 2021

Source
Epstein-Barr virus (EBV) vaccine

Last program update Sep 09, 2021

Source
HIV vaccine

Last program update Aug 05, 2021

Source
Nipah vaccine

Last program update Aug 05, 2021

Source
Antibody against Chikungunya virus

Last program update Aug 05, 2021

Source
IL-2 \n\i Autoimmune disorders

Last program update Sep 09, 2021

Source
Relaxin

Last program update Sep 09, 2021

Source
PD-L1 \n\i Autoimmune hepatitis

Last program update Aug 05, 2021

Source
Personalized Cancer Vaccine (PCV) \n\iSolid tumors/i

Last program update Sep 09, 2021

Source
KRAS vaccine \n\iCRC, NSCLC, pancreatic cancer/i

Last program update Aug 05, 2021

Source
OX40L/IL-23/IL-36y \n\iSolid tumors/lymphoma/i

Last program update Sep 09, 2021

Source
IL-12 \n\iSolid tumors/i

Last program update Sep 09, 2021

Source
VEGF-A \n\iMyocardial ischemia/i

Last program update Sep 09, 2021

Source
PCCA/PCCB\n\iPropionic acidemia (PA)/i

Last program update Sep 09, 2021

Source
MUT \n\iMethylmalonic acidemia (MMA)/i

Last program update Sep 09, 2021

Source
PAH \n\iPhenylketonuria (PKU)/i

Last program update Aug 05, 2021

Source
G6Pase \n\iGlycogen storage disorder type 1a (GSD1a)/i

Last program update Sep 09, 2021

Source
CN-1 \n\iCrigler-Najjar Syndrome Type 1/i

Last program update Sep 09, 2021